Art. -Nr.: HY-N6950

Hederacolchiside A1

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Hederacolchiside A1, isolated from Pulsatilla chinensis, suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway. Hederacolchiside A1 has antischistosomal activity, affecting parasite viability both in vivo and in vitro.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 106577-39-3
Formel: C₄₇H₇₆O₁₆
Molecular Weight:897.10

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Hederacolchiside A1 Chemical Structure

CAS. Nr.: 106577-39-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Publications Citing Use of MedChemExpress (MCE) Hederacolchiside A1

Kaohsiung J Med Sci. 2023 Apr;39(4):377-389. [Abstract]

Customer Validation & Images

Cell Proliferation/Viability AssayIFCell Migration/Invasion AssayWBRT-PCR

Cell Proliferation/Viability Assay
IF
Cell Migration/Invasion Assay
WB
RT-PCR

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Hederacolchiside A1, isolated from Pulsatilla chinensis, suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway^[1]. Hederacolchiside A1 has antischistosomal activity, affecting parasite viability both in vivo and in vitro^[2].

IC₅₀ & Target^[1]

Schistosome

PI3K

mTOR

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle mTOR Isoform-spezifische Produkte anzeigen :

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	15 μM Compound: 27	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
A549	IC₅₀	4 μM Compound: 27	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
A549	IC₅₀	5.41 μM Compound: HA1	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29958763]
DLD-1	IC₅₀	16 μM Compound: 27	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	[PMID: 19200744]
DLD-1	IC₅₀	4 μM Compound: 27	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	[PMID: 19200744]
HCT-116	IC₅₀	2.2 μM Compound: HA1	Antiproliferative activity against human HCT116 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human HCT116 cells after 48 hrs by resazurin reduction assay	[PMID: 27866816]
HCT-116	IC₅₀	8.4 μM Compound: HA1	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
HCT-116	IC₅₀	8.4 μM Compound: HA1	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
HCT-116	IC₅₀	8.4 μM Compound: HA1	Growth inhibition of human HCT116 cells after 48 hrs by MTT assay Growth inhibition of human HCT116 cells after 48 hrs by MTT assay	[PMID: 27866816]
HepG2	IC₅₀	4.21 μM Compound: HA1	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29958763]
HL-60	IC₅₀	2.3 μg/mL Compound: 6	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 10514313]
HL-60	IC₅₀	3.13 μM Compound: HA1	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 29958763]
HT-29	IC₅₀	4.77 μM Compound: HA1	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 29958763]
L02	IC₅₀	7.13 μM Compound: B7	Cytotoxicity against human L02 cells by MTT assay Cytotoxicity against human L02 cells by MTT assay	[PMID: 33964439]
NCI-H460	IC₅₀	2.2 μM Compound: HA1	Antiproliferative activity against human NCI-H460 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by resazurin reduction assay	[PMID: 27866816]
NCI-H460	IC₅₀	3.7 μM Compound: HA1	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
NCI-H460	IC₅₀	3.7 μM Compound: HA1	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
NCI-H460	IC₅₀	3.7 μM Compound: HA1	Growth inhibition of human NCI-H460 cells after 48 hrs by MTT assay Growth inhibition of human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 27866816]
PC-3	IC₅₀	0.85 μM Compound: HA1	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 29958763]
RAW264.7	IC₅₀	0.59 μM Compound: 13	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs by Griess reagent-based assay	[PMID: 30808589]
SGC-7901	IC₅₀	1.7 μM Compound: HA1	Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
SGC-7901	IC₅₀	1.7 μM Compound: HA1	Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
SK-OV-3	IC₅₀	1.3 μM Compound: HA1	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
SK-OV-3	IC₅₀	3.3 μM Compound: HA1	Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
SMMC-7721	IC₅₀	2.2 μM Compound: HA1	Antiproliferative activity against human SMMC7721 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by resazurin reduction assay	[PMID: 27866816]
SMMC-7721	IC₅₀	2.8 μM Compound: HA1	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
SMMC-7721	IC₅₀	2.8 μM Compound: HA1	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
SMMC-7721	IC₅₀	2.8 μM Compound: HA1	Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 27866816]
U-251	IC₅₀	2.2 μM Compound: HA1	Cytotoxicity against human U251 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human U251 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27592134]
U-251	IC₅₀	2.2 μM Compound: HA1	Cytotoxicity against human U251 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human U251 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27592134]
U-251	IC₅₀	2.2 μM Compound: HA1	Antiproliferative activity against human U251 cells after 48 hrs by resazurin reduction assay Antiproliferative activity against human U251 cells after 48 hrs by resazurin reduction assay	[PMID: 27866816]
U-251	IC₅₀	2.2 μM Compound: HA1	Growth inhibition of human U251 cells after 48 hrs by MTT assay Growth inhibition of human U251 cells after 48 hrs by MTT assay	[PMID: 27866816]
U-937	IC₅₀	2.37 μM Compound: HA1	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 29958763]

In Vitro

Hederacolchiside A1 reduces the mitochondrial membrane potential and Bcl-2 protein levels, whereas cleaved caspase-3 was higher^[1].
Hederacolchiside A1 effectively inhibits the phosphorylations of phosphatidylinositol 3 kinase (PI3K), protein kinase B (Akt), and mammalian target of rapamycin (mTOR) ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

hederacolchiside A1 (3.0, 4.5, and 6.0 mg/kg, ip) can significantly inhibit the weight of tumor in an H22 xenograft model^[1].
Hederacolchiside A1 (3.25, 7.5, and 15.0 mg/kg, ig) can significantly inhibit the weight of tumor in nude mice xenograft tumor models using human breast carcinoma MCF-7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 106577-39-3
Appearance Solid
Molecular Weight 897.10
Formel C₄₇H₇₆O₁₆
Color White to off-white
SMILES

C[C@]12[C@]3(C([C@@]4([H])[C@](C(O)=O)(CCC(C)(C)C4)CC3)=CC[C@]1([H])[C@@]5([C@@](C(C)([C@@H](O[C@@]6([H])[C@@H]([C@H]([C@@H](O[C@]7([H])O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)CO)CO6)O)O[C@@]8([H])[C@@H]([C@@H]([C@@H](O)[C@H](C)O8)O)O)CC5)C)([H])CC2)C)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All Cell Proliferation/Viability AssayIFCell Migration/Invasion AssayWBRT-PCR

Sort by:

Journal Impact Factor

Kaohsiung J Med Sci

Repressing IRS1/2 by NT157 inhibits the malignant behaviors of ovarian cancer through inactivating PI3K/AKT/mTOR pathway and inducing autophagy. [Abstract]

2023 Apr;39(4):377-389. PMID: 36727938

Hederacolchiside A1 purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Apr;39(4):377-389. [Abstract]

MTT was adopted to verify the toxicity of Hederacolchiside A1 (Hcol A1) on OVCAR3 cells at different concentrations (0, 1, 2.5, 5, 10, 20 μM).

Hederacolchiside A1 purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Apr;39(4):377-389. [Abstract]

Apoptosis was examined by TUNEL staining assay treated with Hederacolchiside A1 (Hcol A1) (10 μM).

Hederacolchiside A1 purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Apr;39(4):377-389. [Abstract]

Transwell assay was utilized for evaluating the invasive ability of the cells treated with Hederacolchiside A1 (Hcol A1) (10 μM).

Hederacolchiside A1 purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Apr;39(4):377-389. [Abstract]

WB was employed to compare the levels of cleaved Caspase‐8, cleaved Caspase‐9, MCL1, and BCL‐XL treated with Hederacolchiside A1 (Hcol A1) (10 μM).

Hederacolchiside A1 purchased from MedChemExpress. Usage Cited in: Kaohsiung J Med Sci. 2023 Apr;39(4):377-389. [Abstract]

qRT‐PCR was conducted for testing autophagy‐related genes, including ATG5, ATG7, and BECLIN1 treated with Hederacolchiside A1 (Hcol A1) (10 μM).

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (111.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1147 mL

5.5735 mL

11.1470 mL

5 mM

0.2229 mL

1.1147 mL

2.2294 mL

10 mM

0.1115 mL

0.5574 mL

1.1147 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yan-Er Wang, et al. Hederacolchiside A1 suppresses proliferation of tumor cells by inducing apoptosis through modulating PI3K/Akt/mTOR signaling pathway. Chinese Herbal Medicines.Volume 10, Issue 2, April 2018, Pages 215-222

[2]. Kang N, et al. Antischistosomal Properties of Hederacolchiside A1 Isolated from Pulsatilla chinensis. Molecules. 2018 Jun 13;23(6). [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1147 mL	5.5735 mL	11.1470 mL	27.8676 mL
	5 mM	0.2229 mL	1.1147 mL	2.2294 mL	5.5735 mL
	10 mM	0.1115 mL	0.5574 mL	1.1147 mL	2.7868 mL
	15 mM	0.0743 mL	0.3716 mL	0.7431 mL	1.8578 mL
	20 mM	0.0557 mL	0.2787 mL	0.5574 mL	1.3934 mL
	25 mM	0.0446 mL	0.2229 mL	0.4459 mL	1.1147 mL
	30 mM	0.0372 mL	0.1858 mL	0.3716 mL	0.9289 mL
	40 mM	0.0279 mL	0.1393 mL	0.2787 mL	0.6967 mL
	50 mM	0.0223 mL	0.1115 mL	0.2229 mL	0.5574 mL
	60 mM	0.0186 mL	0.0929 mL	0.1858 mL	0.4645 mL
	80 mM	0.0139 mL	0.0697 mL	0.1393 mL	0.3483 mL
	100 mM	0.0111 mL	0.0557 mL	0.1115 mL	0.2787 mL

Keywords

Hederacolchiside A1

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Hederacolchiside A1

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Antiparasitic Compound library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Hederacolchiside A1

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle mTOR Isoform-spezifische Produkte anzeigen

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Hederacolchiside A1 Related Classifications

HY-N6950 Related Classifications